GSK 1940029

Drug Profile

GSK 1940029

Alternative Names: 1940029; GSK1940029

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiacnes
  • Mechanism of Action Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acne vulgaris

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acne-vulgaris in Austria (Topical, Gel)
  • 01 Apr 2015 GlaxoSmithKline completes a phase I trial in Acne vulgaris in Australia (NCT01984801)
  • 01 Feb 2015 GlaxoSmithKline completes a phase I trial in Acne vulgaris (In volunteers) in Australia (NCT01938482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top